Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.
<b/> Reversion mutations associated with PARP inhibitor resistance have been identified in tumors with RAD51C, RAD51D, and PALB2 as well as BRCA1 and BRCA2 mutations. Multiple different reversion mutations can occur in a single patient, and they can be detected by analysis of circulating cell-free DNA. Cancer Discov; 7(9); 937-9. ©2017 AACRSee related article by Kondrashova et al., p. 984See related article by Quigley et al., p. 999See related article by Goodall et al., p. 1006.